Stout served as exclusive financial advisor to Ada Health in the successful completion of its $90 million Series B financing round led by Leaps by Bayer, the impact investment arm of Bayer AG. Additionally, among others, Vitruvian Partners, F4, and Samsung Catalyst Fund joined the round.
The investment will help advance the company’s popular health assessment technology, enabling the digital health pioneer to accelerate its path toward becoming the world's leading personalized operating system for health, as well as to further expand the company’s leading position in the United States. In addition to today’s announcement, Bayer and Ada Health are in discussions about entering into a longer-term strategic partnership to support the company’s healthcare businesses.
The Berlin-based Ada Health has developed a powerful AI-based health assessment and care navigation platform that helps users to understand their symptoms, to identify and differentiate conditions with a high degree of medical accuracy, and to navigate safely to the right care, at the right time. Ada’s consumer app has become the world’s most popular and highest-rated symptom assessment app, with over 23 million assessments completed since its global launch.